DGAP-IRE: SCHWARZ PHARMA AG: Three Months Report 2008 - SCHWARZ PHARMA gets off to a good start

SCHWARZ PHARMA AG / Release of an announcement according to Article 37x of the WpHG [the German Securities Trading Act]

15.05.2008 

Interim report according to Article 37x of the WpHG
---------------------------------------------------------------------------<pre></pre>



May 15, 2008

Three Months Report 2008:

SCHWARZ PHARMA gets off to a good start

SCHWARZ PHARMA group sales increased year-on-year in the first quarter of
2008 1). Neupro(TM) (rotigotine) was the top performer. It was followed by
Prostavasin(TM) (alprostadil), including Edex(TM) (alprostadil), and
Atmadisc(TM)
(fluticasone/salmeterol) as additional key sales drivers. Both products
recorded year-on-year sales growth. The growth in sales of Neupro(TM) and
Prostavasin(TM) (including Edex(TM)) is attributable to the fact that the
figures
include sales from dealings with companies which have ceased to belong to
the scope of consolidation. Overall the sales trend in the first quarter of
2008 was in keeping with the expectations.

The operating result of the SCHWARZ PHARMA group in the first quarter,
compared to the prior year period, showed a satisfactory trend.

The group's financial result improved considerably year-on-year. Within the
scope of integration into the UCB group, SCHWARZ PHARMA granted an
interest-bearing vendor loan, generating interest income in the first
quarter which was distinctly higher than that recorded in the previous
year.

The net result was hence better than in the same quarter of the prior year.

For 2008, SCHWARZ PHARMA plans to make additional investments at the
production sites in Shannon/Ireland (fine chemicals) and Zwickau/Germany
(bulk manufacture). These projects are progressing as planned.

SCHWARZ PHARMA is maintaining its sales estimate of around EUR400 million
for full fiscal year 2008. The impact of the inability to deliver
Neupro(TM) in the USA, announced in March 2008, and the effect of possible
measures to restore the ability to deliver are not foreseeable at present.
SCHWARZ
PHARMA will in all likelihood have a better insight into the situation at
the time when its half-year financial report is published. Due to the
start-up expenses for producing the drug fesoterodine, SCHWARZ PHARMA
continues to expect a negative net result for 2008. This outlook does not
include earnings from the divestment of products or partnerships.

1) As part of the process of integrating SCHWARZ PHARMA AG into the UCB
group, 13 affiliated com-panies ceased to belong to the company's scope of
consolidation as per end of fiscal year 2007. All details on the prior year
period only relate to continuing operations.




SCHWARZ PHARMA AG (seated in Monheim, Germany) is a member of the UCB
group, Brussels/Belgium (www.ucb-group.com). UCB is listed on the Euronext
exchange in Brussels and holds around 89% of all SCHWARZ PHARMA shares.

UCB is a leading global biopharmaceutical company whose focus is on
researching, developing, and commercializing innovative pharmaceutical and
biotechnological products in the fields Central Nervous System, allergic
and respiratory diseases, immunological and inflammatory diseases, and
oncology. UCB achieved sales of EUR3.6 billion in 2007 and employs more
than
11.000 workers in 40 countries.

Contact: Sylvia Heitzer,Tel: +49 2173 48 1238; Antje Witte, Tel.: +32 2 559
9414
Internet: www.schwarzpharma.com

This press release contains assumptions, expectations, and forecasts on
future sector trends, on future legal and commercial developments, and on
the future development of the company. These assumptions, expectations, and
forecasts are no guarantee for future performance and are subject to change
at any time. Consequently, future reports and the factual circumstances of
the company may deviate materially from the outlook presented by the above.
The company assumes no responsibility for updating such assumptions,
expectations, and forecasts on future sector trends, on future legal and
commercial developments, and on the future development of the company.

DGAP 15.05.2008 
---------------------------------------------------------------------------
Language:     English
Issuer:       SCHWARZ PHARMA AG
              Alfred-Nobel-Str. 10
              40789 Monheim
              Deutschland
Internet:     www.schwarzpharma.com
End of News                                     DGAP News-Service
---------------------------------------------------------------------------